Recent

% | $
Quotes you view appear here for quick access.

Pharmos Corp. Message Board

  • fdzllc fdzllc Oct 3, 2003 12:40 AM Flag

    Last 12 months- My interpretation

    From: "Gabe Fernandez MD"
    Date: Thu Oct 2, 2003 11:22 pm
    Subject: Last 12 months MY INTERPRETATIO


    I remember before when the FDA requested further data from Pharmos
    before approving the IND. There was a substantial delay until
    Pharmos presented added studies which included testing in simians.
    Tbird, office boy Cheoff,brkmark the priapists and other Phenoms volunteered. My eternal thanks to them and their masters since it permitted us to buy the stock at bargain prices.

    Pharmos performed well,submitted the data and the IND was finally approved several
    months ago. The studioes in the USA which were predicted by our Bashers Phenoms would never occur. They were wrong. We have 15 centers going.
    Pharmos also stated at the last meeting that we qualified for Fast Track and Orphan Drug status. Pharmos requested the Fast
    Track and it was granted by the FDA. The next logical news will be
    the granting of Orphan Drug status.
    Granted that both do not
    gurantee the approval or good results of the science of Dexanabinol
    but it also establishes an important point. The FDA request and we
    comply and apparently they approve of our cooperation. The FDA is
    aware of the significance of Dexanabinol as the only Neuroprotectant
    available in the near future. In essence they are aware of the need of such a product.

    We hear that the FDA acts in mysterious ways at times but we also
    read that the attitude of the FDA is more relaxed and cooperative in
    establishing new drugs. Pharmos by its submission of data requested
    by the FDA in a positive manner should have made the FDA aware of Pharmos due diligence and Dexanabinol's need not only in TBI but in the Neuroprotectant arena.

    The question is when will Big Pharma and the investment Biotech
    analyst arena realize that indeed there may be something to this
    small company. The need of new products by Big Pharma is real,as we see reported.

    The catalysts for our company will occur in sequence:
    1- Approval of Orphan drug status this Q.
    2- Completion of enrollment for Phase III TBI in early 2004 or as I believe and hope this year.
    3- Report on Phase IIa MCI-CABG Dex trials and as I believe a succesful trial. Expected time table for this event 1st Q 2004
    This last event is the one that will finally alert the Big Pharma
    giants that indeed Pharmos would be a good marriage partner. The
    possibility of having a drug with these many disease entity
    indications is so large that it would be in their best interest
    to have a piece of the action.
    It is PROBABLE that Aviv will still want to wait for the submission of the NDA for TBI. I hope that it occurs sooner but
    eventually our long wait will be rewarded.
    4- Report on TBI results which either way could be a bombshell.I firmly believe in the positive aspects of the same.
    5- Submission of NDA.
    6- Approval of same by regulatory agencies. Believe Israel should be the first.

    My Parsians friends I have been attacked as a cheer leader and crony of Pharmos. I many years ago mentioned my belief that Dexanabinol, if effective, would be a drug that would prevent or at least modify
    the POST INSULT CASCADE. This insult been of traumatic,inflamatory,infectious,degenerative cause etc of any ORGAN not
    only BRAIN. Can you imagine not only the significance of reducing
    the area of ischemia in a stroke,think also about reducing the area
    of infarct in a heart attack.
    Some Bashers even admit that at best
    we are a 5-10 dollar company. That is fine if our point of entry is
    now. gl gabe

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • All said with whoafully little data to back it up it true effectiveness. Thats their biggest problem, they just don't have enough data to prove anything at this point. P2 barely showed more than statistical chance of anything positive. Thats why the price is low, not because this type of product is not need or anything else. Just pointing out the facts in case anyone thinks this is a slam dunk.

      • 4 Replies to reallynolie
      • reallynollie:
        Your point that:
        "All said with whoafully little data to back it up it true effectiveness."

        Point is correct the science of Dex has not been proven as we speak but there are many clues that point to the probabillity of success. In essence, it is like a legal case, we have a great deal of circumstantial evidence that point towards the main point NEUROPROTECTION
        1- Phase II TBI results
        2-Fact that we are in Phase III with no
        safety issues.
        3-Why start a new study CABG-MCI unless there
        was confidence in success. The money of
        Pharmos is indeed tight.
        4-The multitude of increase research in
        Cannabinoids in other fields Pain,anti
        angiogenesis etc
        5-Granting of Fast track even though it does
        not in itself affect approval does indeed
        confirm need of product.
        6-Comments from leading Neurosurgical TBI
        experts.
        7-Endorsement of Phase III by EBIC-ABIC
        8-Participation of EBIC-ABIC in the protocol
        development. An area responsible for
        previous TBI failures.
        9- Nature of protocol and its strictness which assures that those accepted are those most likely to suffer from ICP problems and Neurological deterioration. Both points of major importance in TBI as Phase II showed.
        10- Finally reports and analysis of Dexanabinol by other trauma and neuroanesthesia leaders.

        The clues of success are there and it can be purchased at 2.60/share. gl gabe

      • name source or stop writing boolshit

      • >>> All said with whoafully little data to back it up it true effectiveness. Thats their biggest problem, they just don't have enough data to prove anything at this point. P2 barely showed more than statistical chance of anything positive. Thats why the price is low, not because this type of product is not need or anything else. Just pointing out the facts in case anyone thinks this is a slam dunk. <<<

        That's bullshit, just pure bullshit. Stat sig numbers were obtained, thru ALL three cohorts in ICP control, CPP numbers and hypotensive episodes. THAT are the facts. Be so kind to note the sources of your 'facts'... I'll respond in kind. Let's hear it...

      • "All said with whoafully little data to back it up it true effectiveness."..."P2 barely showed more than statistical chance of anything positive."

        source?

        k, thx, bye.

 
PARS
0.0425+0.0015(+3.66%)Sep 2 3:25 PMEDT